Loading…
Eli Lilly and Company has announced a definitive agreement to acquire Adverum Biotechnologies, including its lead product candidate Ixo-vec, a Phase 3 gene therapy for wet age-related macular degeneration.
“Ixo-vec has the potential to transform wAMD treatment from a paradigm of chronic care with repeated intravitreal injections to a convenient one-time therapy”investor.lilly.com
Summarized from public sources; check the original articles before acting on it.